Oxford Biomedica PLC 2022 Annual Report and Accounts (8544X)
28 Abril 2023 - 1:59AM
UK Regulatory
TIDMOXB
RNS Number : 8544X
Oxford Biomedica PLC
28 April 2023
Oxford Biomedica PLC
2022 Annual Report and Accounts
London, UK - 28 April 2023: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica", "the Company" or "the Group"), a quality and
innovation-led viral vector CDMO, gives notice that the 2022 Annual
report and accounts is now available on the "Investors" section of
the Group's website at www.oxb.com. In accordance with Listing rule
9.6.1, the 2022 Annual report and accounts has also been submitted
to the Financial Conduct Authority for publication through the
National Storage Mechanism and will shortly be available for
inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Further copies of the 2022 Annual report and accounts are
available from the Company Secretary, Oxford Biomedica plc,
Windrush Court, Transport Way, Oxford, OX4 6LT, United Kingdom
(telephone number: +44 (0) 1865 783 000). The Company confirms
that, in compliance with DTR 6.3.5(1A), the regulated information
required under DTR 6.3.5, is available in unedited full text within
the Annual Report available on the National Storage Mechanism and
in compliance with DTR 6.3.5(3) is available on the Company's
website as noted above.
For further information, please
contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
Notes for editors
Oxford Biomedica (LSE: OXB) is a quality and innovation-led
viral vector CDMO with a mission to enable its clients to deliver
life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the
Company has more than 25 years of experience in viral vectors; the
driving force behind the majority of gene therapies. The Company
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations across Oxfordshire, UK and a US-based
subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US.
Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on
LinkedIn, Twitter and YouTube.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSUWVNROBUSURR
(END) Dow Jones Newswires
April 28, 2023 02:59 ET (06:59 GMT)
Oxford Biomedica (AQSE:OXB.GB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Oxford Biomedica (AQSE:OXB.GB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024